Study Summary
This trialwill test if radiation therapy helps treat metastatic renal cancer in patients using an immune checkpoint inhibitor.
- Kidney Cancer
- Oligoprogressive
- Progression
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to two years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Stereotactic Body Radiation Therapy
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Stereotactic Body Radiation Therapy · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 12 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Do you have any open recruitment spots for this trial?
"Affirmative, according to clinicaltrials.gov this study is still recruiting volunteers. The recruitment effort was initiated on August 8th 2022 and recently updated on December 6th of the same year. 30 participants are needed at a single medical facility." - Anonymous Online Contributor
What risks have been associated with Stereotactic Body Radiation Therapy?
"Our team at Power rated Stereotactic Body Radiation Therapy's safety a 2 since the trial is in Phase 2, which provides evidence of its security but no proof that it works." - Anonymous Online Contributor
What is the enrollment size of this clinical trial?
"Affirmative, the information available on clinicaltrials.gov reflects that this study is actively recruiting participants; first posted in August 2022 and last updated December 6th of the same year. To complete the trial, 30 patients are needed at one site only." - Anonymous Online Contributor